Sign in
CompletedPhase 2

Oxytocin to Treat PTSD

Key facts

Who runs it
VA Office of Research and Development
Where
Charleston and San Francisco, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
180 people enrolled
Started
1 Jan 2021
Ended
31 Aug 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Oxytocin
  • Placebo
Record updated
11 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Veteran
  • Any race or ethnicity
  • Able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of the assessment instruments (> 26 on the Mini Mental Status Exam)
  • Meet DSM-5 diagnostic criteria for current (i.e., past 6 months) PTSD (assessed via the CAPS-5); participants may also meet criteria for a mood disorder (except bipolar affective disorder, see Exclusion Criteria); anxiety disorders (e.g. panic disorder, agoraphobia, social phobia, generalized anxiety disorder, or obsessive compulsive disorder)
  • Participants taking psychotropic medications will be required to be maintained on a stable dose for at least four weeks before study initiation

Who cannot take part

  • Participants on maintenance anxiolytic, antidepressant, or mood stabilizing medications, which have been initiated during the past 4 weeks
  • Meeting DSM-5 criteria for a history of or current psychotic or bipolar affective disorders, or with current suicidal or homicidal ideation and intent; those participants will be referred clinically
  • Participants who present a serious suicide risk or are likely to require hospitalization during the study
  • Pregnancy or breastfeeding for women

Where in United States

  • Ralph H. Johnson VA Medical Center, Charleston, SCCharleston, United States
  • San Francisco VA Medical Center, San Francisco, CASan Francisco, United States

About the trial

What the trial wants to find out

Posttraumatic stress disorder (PTSD) is a chronic, debilitating condition that disproportionately affects Veterans. Prolonged Exposure (PE) therapy is a "gold standard" treatment for PTSD. However, approximately one-third of Veterans fail to receive an adequate dose of treatment because they prematurely drop out of PE therapy. There is also room to improve PE treatment outcomes. Consistent with the VA Office of Research and Development initiative to develop effective treatments for PTSD, the proposed randomized clinical trial will examine the ability of oxytocin (as compared with placebo) combined with PE to reduce PTSD symptom severity, improve the rate of PTSD symptom reduction, and to enhance PE treatment retention and adherence. This two-site study will leverage the investments made in the nationwide rollout off PE therapy and has the potential to significantly improve mental health care among Veterans, advance the science in this area, and identify mechanisms underlying positive PTSD treatment response. Participants may choose to complete this research study via home-based telemedicine (HBT) care (i.e. service delivery to patients in their homes using consumer friendly, video-conferencing technology). HBT sessions will be delivered via standard desk, laptop computer, tablet, or smartphone using VA approved applications. All procedures that take place via telemedicine will be performed and completed as though they were in-person/in-office

The 2 groups in the trial

  • OxytocinTreatment being tested

    40 IU intranasal oxytocin

  • PlaceboPlacebo, for comparison

    intranasal saline spray

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Enhancing Prolonged Exposure Therapy for PTSD With Oxytocin
Publications
Record updated
11 March 2026